A human pilot study presented at the SIO meeting in Houston showed that AHCC can eliminate HPV infection in women. Five out of ten participants achieved a negative HPV test result after taking AHCC orally for up to five months, suggesting a potential breakthrough in cancer prevention and treatment.
Researchers from the University of Ottawa and Drexel University have been awarded the 'Best of Research' award for their study on the mode of action of AHCC, an alpha-glucan rich immune modulator. The study demonstrated that AHCC can stimulate intestinal immunity and increase IgA+ immune cells in the intestines.
A preclinical study suggests that AHCC supplement can eliminate HPV infections and may have a role in preventing HPV-related cancers. The study found durable responses after treatment with AHCC for up to 90 days, with no side effects observed.
The McKesson Foundation has awarded $1.3 million in Mobilizing for Health Research grants to six U.S. institutions to study the use of mobile technology in diabetes care and management. The studies aim to improve patient outcomes and reduce healthcare costs through innovative mobile health solutions.
A study found that Concord grape juice increased high-density lipoprotein (HDL) levels and decreased inflammatory markers, including soluble CD40 ligand, in patients with coronary artery disease. The positive effects were attributed to the polyphenolic compounds in the grape juice.
Researchers found that Concord grape juice improved short-term memory and neuro-motor skills in senescent rats, with significant improvements seen in tests measuring spatial learning and balance. The study suggests that high levels of natural antioxidants in the grape juice may be responsible for these benefits.
The Tylenol Scholarship is one of the largest merit scholarship programs in the United States for all health-related studies. Since its inception in 1991, more than $6 million in scholarship grants have been awarded to over 5,000 students by McNeil Consumer & Specialty Pharmaceuticals.
A 12-week study found that drinking Concord grape juice daily reduced systolic and diastolic blood pressure in hypertensive men by nearly six points. The results, presented at the FASEB annual meeting, suggest a possible mechanism of action involving improved arterial wall flexibility.
A recent study found that high levels of Lp-PLA2 and CRP are associated with an increased risk of coronary heart disease, even in patients with 'normal' LDL cholesterol levels. The study used the PLAC test to measure Lp-PLA2 levels in participants and found significant associations between Lp-PLA2, hs-CRP, and CHD incidence.
A study published in the American Journal of Clinical Nutrition found that drinking Concord grape juice for two weeks increases the resistance of LDL cholesterol to oxidation. This reduction in oxidative stress may contribute to a lower risk of heart disease and stroke.
A study found that Actonel significantly slows deterioration in trabecular bone microarchitecture after just one year, while a placebo had no such effect. This suggests that protection of bone microarchitecture may play an important role in bone health.
A recent study published in Pediatrics found that babies with a history of colic are more likely to experience symptoms after drinking apple juice, while white grape juice has no significant impact. The research suggests that parents should choose white grape juice as the best option for their baby if they have had colic.
A Phase II trial found an overall response rate of 78% with the combination, compared to 75% with single-agent treatment. The addition of Navelbine to Herceptin was well-tolerated, with no severe side effects reported.
Durable responses were reported with Bexxar in a clinical trial of 582 patients with relapsed or refractory low-grade NHL. A total of 57% of patients achieved an overall response, while 28% showed a complete response. The average follow-up was 1.3 years, and half of the patients remained in remission for over 14 months.
A multicenter study published in the American Journal of Cardiology found that adding Benecol spread to a patient's diet can lower LDL-C and total cholesterol levels by 17% and 12%, respectively. The study also showed that the cholesterol-lowering effect of Benecol was evident as early as the second week of treatment.